The firm manages the investments in innovation for a large integrated delivery network health system with over 15 hospitals and 35,000 providers and employees. The firm is responsible for sourcing external innovation investments outside of the hospital system, and seeks early-stage co-investment opportunities led by quality lead venture firms, coupled with a strong emphasis on co-development opportunities with early-stage companies where the firm’s expertise in clinical, population health, health insurance services, and digital security can be most value-adding. The firm is open to global opportunities.
Currently, the firm is most interested in investments in digital health, HCIT, and process transformation opportunities, and will consider medical devices (predominantly of the wearables, monitoring types). The firm does not consider therapeutics companies at this time.
The firm is opportunistic, but examples of previous engagements have been in technologies targeting care administration/operations, cancer, cardiology, neuroscience and ALS, and even health-focused cybersecurity. As the firm heavily weights the ability to be an active co-development partner, it is open to the earliest stage digital health technologies, but companies who have yet to close a Seed round will be considered too early.
The firm does not have specific company or management team requirements. The Investment Office intends to leverage lead VC due diligence in its co-investment assessments.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply